Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to $97.8 million.

  • Cytokinetics' Share-based Compensation rose 21.06% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.0 million, marking a year-over-year increase of 18.61%. This contributed to the annual value of $97.8 million for FY2024, which is 35.77% up from last year.
  • Per Cytokinetics' latest filing, its Share-based Compensation stood at $97.8 million for FY2024, which was up 35.77% from $72.1 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Share-based Compensation registered a high of $97.8 million during FY2024, and its lowest value of $17.6 million during FY2020.
  • Its 3-year average for Share-based Compensation is $72.6 million, with a median of $72.1 million in 2023.
  • Data for Cytokinetics' Share-based Compensation shows a peak YoY surged of 78.34% (in 2022) over the last 5 years.
  • Cytokinetics' Share-based Compensation (Yearly) stood at $17.6 million in 2020, then skyrocketed by 52.28% to $26.8 million in 2021, then skyrocketed by 78.34% to $47.9 million in 2022, then surged by 50.60% to $72.1 million in 2023, then skyrocketed by 35.77% to $97.8 million in 2024.